Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/17293390

Download in:

View as

General Info

PMID
17293390